Testing times

Abstract

Dr Rhiannon Sanders, Director of Market Development at Pyrosequencing AB, has maintained a special interest in pharmacogenomics since 1997. Dr Sanders discussed with Expert Review of Molecular Diagnostics the increasing acceptance and usage of genetic testing within modern healthcare and highlighted some current controversies and uncertainties. Dr Sanders joined Pyrosequencing AB in January 2001 and has held senior positions within Eurona Medical and Gemini Genomics. Pyrosequencing has recently focused on the expansion of its proprietary DNA sequencing technology to target new markets. Dr Sanders was instrumental in initiating the Molecular Diagnostics Business Unit within Pyrosequencing and in her current capacity has responsibility for Applications and Market Development for Europe. Dr Sanders has a BSc Honours in Biochemistry from Bath University, UK and a PhD in Microbiology/Molecular Biology from Warwick University, UK.